留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

阿帕替尼在恶性肿瘤治疗中的临床应用与研究进展

龚晓斌 刘诗怡 夏天一 位华 陈万生

龚晓斌, 刘诗怡, 夏天一, 位华, 陈万生. 阿帕替尼在恶性肿瘤治疗中的临床应用与研究进展[J]. 药学实践与服务, 2018, 36(2): 103-107,130. doi: 10.3969/j.issn.1006-0111.2018.02.002
引用本文: 龚晓斌, 刘诗怡, 夏天一, 位华, 陈万生. 阿帕替尼在恶性肿瘤治疗中的临床应用与研究进展[J]. 药学实践与服务, 2018, 36(2): 103-107,130. doi: 10.3969/j.issn.1006-0111.2018.02.002
GONG Xiaobin, LIU Shiyi, XIA Tianyi, WEI Hua, CHEN Wansheng. Clinical application and research progress of apatinib in cancer treatment[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(2): 103-107,130. doi: 10.3969/j.issn.1006-0111.2018.02.002
Citation: GONG Xiaobin, LIU Shiyi, XIA Tianyi, WEI Hua, CHEN Wansheng. Clinical application and research progress of apatinib in cancer treatment[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(2): 103-107,130. doi: 10.3969/j.issn.1006-0111.2018.02.002

阿帕替尼在恶性肿瘤治疗中的临床应用与研究进展

doi: 10.3969/j.issn.1006-0111.2018.02.002
基金项目: 上海市科学技术委员会项目(13DZ1930600)

Clinical application and research progress of apatinib in cancer treatment

  • 摘要: 抗血管生成靶向治疗是近年来肿瘤治疗的研究热点。其中,血管新生抑制剂阿帕替尼是我国自主研制的1.1类新药。临床前研究和临床试验研究表明,阿帕替尼对胃癌、肺癌、乳腺癌等多种肿瘤均具有显著的抑制活性,其安全性和有效性良好。然而,阿帕替尼的相关研究显示,目前仍存在作用机制不十分明确等问题。因此,开展进一步研究以不断提高药物的安全性、有效性和经济性,是阿帕替尼广泛应用于临床的前提。总结阿帕替尼在国内外研究现状,从作用机制、药动学过程、临床疗效、安全性和生物标志物等角度进行归纳,探讨了近年来阿帕替尼研究的热点与争议问题,实现对阿帕替尼的临床应用前景展望。
  • [1] Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016, 34(13):1448-1454.
    [2] Geng R, Li J. Apatinib for the treatment of gastric cancer[J]. Expert Opin Pharmacother, 2015, 16(1):117-122.
    [3] Tian S, Quan H, Xie C,et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J]. Cancer Sci, 2011, 102(7):1374-1380.
    [4] Li J, Qin S, Xu J,et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:Results from a randomized, placebo-controlled, parallel-arm, phase Ⅱ trial[J]. J Clin Oncol, 2013, 31(26):3219-3225.
    [5] Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression[J]. Crit Rev Oncol Hematol, 2007, 62(3):179-213.
    [6] Folkman J, Merler E, Abernathy C,et al. Isolation of a tumor factor responsible for angiogenesis[J]. J Exp Med, 1971, 133(2):275-288.
    [7] Sia D, Alsinet C, Newell P,et al. VEGF signaling in cancer treatment[J]. Curr Pharm Des, 2014, 20(17):2834-2842.
    [8] Muller YA, Li B, Christinger HW,et al. Vascular endothelial growth factor:crystal structure and functional mapping of the kinase domain receptor binding site[J].Proc Natl Acad Sci USA, 1997, 94(14):7192-7197.
    [9] Holmes K, Roberts OL, Thomas AM,et al. Vascular endothelial growth factor receptor-2:structure, function, intracellular signalling and therapeutic inhibition[J]. Cell signal, 2007, 19(10):2003-2012.
    [10] Olsson AK, Dimberg A, Kreuger J,et al. VEGF receptor signalling-in control of vascular function[J]. Nat Rev Mol Cell Biol, 2006, 7(5):359-371.
    [11] Vesely DL. Family of peptides synthesized in the human body have anticancer effects[J]. Anticancer Res, 2014, 34(4):1459-1466.
    [12] Koch S, Tugues S, Li X,et al. Signal transduction by vascular endothelial growth factor receptors[J]. Biochem J, 2011, 437(2):169-183.
    [13] Peng S, Zhang Y, Peng H,et al. Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by apatinib[J]. Cancer Lett, 2016, 373(2):193-202.
    [14] Ji G, Hong L, Yang P. Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib:a case report[J]. Onco Targets Ther, 2016, 9:643-647.
    [15] Zhou N, Liu C, Hou H,et al. Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma[J]. Oncotarget, 2016, 7(44):72373-72379.
    [16] Peng H, Zhang Q, Li J,et al. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma[J]. Oncotarget, 2016, 7(13):17220-17229.
    [17] Ilson DH. Targeting the vascular endothelial growth factor pathway in gastric cancer:a hit or a miss?[J]. J Clin Oncol, 2016, 34(13):1431-1432.
    [18] Moehler M, Mueller A, Hartmann JT,et al. An open-label, multicentre biomarker-oriented AIO phase Ⅱ trial of sunitinib for patients with chemo-refractory advanced gastric cancer[J]. Eur J Cancer, 2011, 47(10):1511-1520.
    [19] Bang YJ, Kang YK, Kang WK,et al. Phase Ⅱ study of sunitinib as second-line treatment for advanced gastric cancer[J]. Invest New Drugs, 2011, 29(6):1449-1458.
    [20] Yi JH, Lee J, Lee J,et al. Randomised phase Ⅱ trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum[J]. Br J Cancer, 2012, 106(9):1469-1474.
    [21] Martin-Richard M, Gallego R, Pericay C,et al. Multicenter phase Ⅱ study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study[J]. Invest New Drugs, 2013, 31(6):1573-1579.
    [22] Sun W, Powell M, O'Dwyer PJ,et al. Phase Ⅱ study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma:ECOG 5203[J]. J Clin Oncol, 2010, 28(18):2947-2951.
    [23] Ohtsu A, Shah MA, Van Cutsem E,et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer:a randomized, double-blind, placebo-controlled phase Ⅲ study[J]. J Clin Oncol, 2011, 29(30):3968-3976.
    [24] Shen L, Li J, Xu J,et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer:randomized, double-blind, phase Ⅲ study (AVATAR study)[J]. Gastric Cancer, 2015, 18(1):168-176.
    [25] Fuchs CS, Tomasek J, Yong CJ,et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD):an international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2014, 383(9911):31-39.
    [26] Wilke H, Muro K, Van Cutsem E,et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW):a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11):1224-1235.
    [27] Tarazona N, Gambardella V, Huerta M,et al. Personalised treatment in gastric cancer:myth or reality?[J]. Curr Oncol Rep, 2016, 18(7):41.
    [28] Park DJ, Thomas NJ, Yoon C,et al. Vascular endothelial growth factor a inhibition in gastric cancer[J]. Gastric Cancer, 2015, 18(1):33-42.
    [29] Van Cutsem E, de Haas S, Kang YK,et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer:a biomarker evaluation from the AVAGAST randomized phase Ⅲ trial[J]. J Clin Oncol, 2012, 30(17):2119-2127.
    [30] Tong XZ, Wang F, Liang S,et al. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells[J]. Biochem Pharmacol, 2012, 83(5):586-597.
    [31] Mi YJ, Liang YJ, Huang HB,et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters[J]. Cancer Res, 2010, 70(20):7981-7991.
    [32] Ding J, Chen X, Gao Z,et al. Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans[J]. Drug Metab Dispos, 2013, 41(6):1195-1210.
    [33] Li J, Zhao X, Chen L,et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies[J]. BMC Cancer, 2010, 10:529.
    [34] Lin D, Wang Z, Li J,et al. The effect of apatinib on the metabolism of carvedilol both in vitro and in vivo[J]. Pharmacology, 2016, 97(1-2):31-37.
    [35] Yu M, Gao Z, Dai X,et al. Population pharmacokinetic and covariate analysis of apatinib, an oral tyrosine kinase inhibitor, in healthy volunteers and patients with solid tumors[J]. Clin Pharmacokinet, 2017, 56(1):65-76.
    [36] Hu X, Cao J, Hu W,et al. Multicenter phase Ⅱ study of apatinib in non-triple-negative metastatic breast cancer[J]. BMC Cancer, 2014, 14:820.
    [37] Hu X, Zhang J, Xu B,et al. Multicenter phase Ⅱ study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer[J]. Int J Cancer, 2014, 135(8):1961-1969.
    [38] Fan M, Zhang J, Wang Z,et al. Phosphorylated VEGFR2 and hypertension:potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy[J]. Breast Cancer Res Treat, 2014, 143(1):141-151.
    [39] Zhang L, Shi M, Huang C,et al. A phase Ⅱ, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens[J]. J Clin Oncol,2012, 30(15_suppl):7548.
    [40] Qin S. Apatinib in Chinese patients with advanced hepatocellular carcinoma:a phase Ⅱ randomized, open-label trial[J]. J Clin Oncol, 2014, 32(15_suppl):4019.
    [41] Li XF, Tan YN, Cao Y,et al. A case report of gastrointestinal hemorrhage and perforation during apatinib treatment of gastric cancer[J]. Medicine (Baltimore), 2015, 94(39):e1661.
    [42] Ding C, Zhang C, Zhang M,et al. Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2[J]. Future Med Chem, 2014, 6(16):1771-1789.
    [43] Loges S, Mazzone M, Hohensinner P,et al. Silencing or fueling metastasis with VEGF inhibitors:Antiangiogenesis revisited[J]. Cancer Cell, 2009, 15(3):167-170.
    [44] Roviello G, Ravelli A, Fiaschi AI,et al. Apatinib for the treatment of gastric cancer[J]. Expert Rev Gastroenterol Hepatol, 2016, 10(8):887-892.
    [45] Lin C, Wang S, Xie W,et al. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway[J]. Oncotarget, 2016, 7(37):59236-59244.
  • [1] 方宇昕, 李育, 刘宝姝, 董国强.  磷脂酰肌醇蛋白聚糖-3靶向治疗肝细胞癌的研究进展 . 药学实践与服务, 2023, 41(10): 586-593. doi: 10.12206/j.issn.2097-2024.202307047
    [2] 王道鑫, 张添光, 缪朝玉.  血管内皮细胞线粒体氧化应激与动脉粥样硬化 . 药学实践与服务, 2023, 41(6): 329-334, 392. doi: 10.12206/j.issn.2097-2024.202205116
    [3] 王宏播, 卞康晴, 郭灵怡, 代宇, 俞媛.  外泌体用于疾病诊疗和药物递送的研究进展 . 药学实践与服务, 2023, 41(5): 265-272, 320. doi: 10.12206/j.issn.2097-2024.202207022
    [4] 宋志兵, 张倩, 章越凡, 邱彦, 李铁军.  乌帕替尼对氧糖剥夺/复氧后BV2细胞极化的影响 . 药学实践与服务, 2021, 39(2): 112-117. doi: 10.12206/j.issn.1006-0111.202012006
    [5] 赵全凤, 龚玉竹, 谢赣丰, 夏培元, 唐敏.  临床药师参与晚期直肠神经内分泌瘤患者的药学服务 . 药学实践与服务, 2019, 37(6): 559-562. doi: 10.3969/j.issn.1006-0111.2019.06.017
    [6] 姜文丽, 黄才国.  晚期非小细胞肺癌靶向治疗的研究进展 . 药学实践与服务, 2016, 34(4): 301-304,333. doi: 10.3969/j.issn.1006-0111.2016.04.004
    [7] 赵佳丽, 陈秋红, 李红娜, 曾莉莉, 叶永贤, 费燕.  神经病理性疼痛的药物治疗进展 . 药学实践与服务, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
    [8] 于淼, 毛峻琴.  基因miRNA-34a靶向纳米复合物抗前列腺癌细胞增殖的作用研究 . 药学实践与服务, 2015, 33(6): 539-543. doi: 10.3969/j.issn.1006-0111.2015.06.016
    [9] 陈婷, 鲁莹.  载抗肿瘤药物纳米靶向给药系统的研究进展 . 药学实践与服务, 2011, 29(3): 176-178,196.
    [10] 黄景彬, 钟延强.  乳腺癌靶向治疗的新策略 . 药学实践与服务, 2011, 29(5): 324-327.
    [11] 官东秀, 冯祚臻.  临床药师对1例服用分子靶向药物吉非替尼的肿瘤患者的药学监护 . 药学实践与服务, 2010, 28(4): 310-312.
    [12] 张琪, 夏爱军.  重组人血管内皮抑制素联合化疗治疗非小细胞肺癌疗效的Meta分析 . 药学实践与服务, 2010, 28(6): 451-455.
    [13] 刘厚佳, 李铁军, 邱彦, 芮耀诚, 卫立辛, 吴孟超, 张黎.  欧芹素乙对人脐静脉内皮细胞的保护作用及对血管内皮生长因子表达的影响 . 药学实践与服务, 2009, 27(2): 94-98.
    [14] 薛龙, 孙爱军.  恶性肿瘤靶向治疗方法的进展及应用 . 药学实践与服务, 2008, (2): 81-83.
    [15] 贾国强, 杨亚青.  吉非替尼治疗非小细胞肺癌的临床疗效观察 . 药学实践与服务, 2007, (6): 399-400.
    [16] 施利兴, 闫政.  中药保护血管内皮细胞功能研究进展 . 药学实践与服务, 2005, (6): 356-358.
    [17] 施利兴, 闫政.  中药有效成分对血管内皮细胞的保护作用 . 药学实践与服务, 2005, (5): 263-265.
    [18] 张黎, 邱彦, 芮耀诚, 李铁军, 刘厚佳.  缺氧对血管内皮生长因子诱导主动脉内皮细胞通透性增加的调控研究 . 药学实践与服务, 2004, (3): 135-137.
    [19] 郑礼宝, 黄卫东, 陈静, 张弘, 付江洲.  阿达帕林凝胶治疗寻常痤疮临床观察 . 药学实践与服务, 2002, (1): 10-11,28.
    [20] 邱彦, 芮耀诚.  血管内皮生长因子血管通透作用研究进展 . 药学实践与服务, 2002, (4): 228-231.
  • 加载中
计量
  • 文章访问数:  2864
  • HTML全文浏览量:  306
  • PDF下载量:  719
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-11-05
  • 修回日期:  2018-01-09

阿帕替尼在恶性肿瘤治疗中的临床应用与研究进展

doi: 10.3969/j.issn.1006-0111.2018.02.002
    基金项目:  上海市科学技术委员会项目(13DZ1930600)

摘要: 抗血管生成靶向治疗是近年来肿瘤治疗的研究热点。其中,血管新生抑制剂阿帕替尼是我国自主研制的1.1类新药。临床前研究和临床试验研究表明,阿帕替尼对胃癌、肺癌、乳腺癌等多种肿瘤均具有显著的抑制活性,其安全性和有效性良好。然而,阿帕替尼的相关研究显示,目前仍存在作用机制不十分明确等问题。因此,开展进一步研究以不断提高药物的安全性、有效性和经济性,是阿帕替尼广泛应用于临床的前提。总结阿帕替尼在国内外研究现状,从作用机制、药动学过程、临床疗效、安全性和生物标志物等角度进行归纳,探讨了近年来阿帕替尼研究的热点与争议问题,实现对阿帕替尼的临床应用前景展望。

English Abstract

龚晓斌, 刘诗怡, 夏天一, 位华, 陈万生. 阿帕替尼在恶性肿瘤治疗中的临床应用与研究进展[J]. 药学实践与服务, 2018, 36(2): 103-107,130. doi: 10.3969/j.issn.1006-0111.2018.02.002
引用本文: 龚晓斌, 刘诗怡, 夏天一, 位华, 陈万生. 阿帕替尼在恶性肿瘤治疗中的临床应用与研究进展[J]. 药学实践与服务, 2018, 36(2): 103-107,130. doi: 10.3969/j.issn.1006-0111.2018.02.002
GONG Xiaobin, LIU Shiyi, XIA Tianyi, WEI Hua, CHEN Wansheng. Clinical application and research progress of apatinib in cancer treatment[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(2): 103-107,130. doi: 10.3969/j.issn.1006-0111.2018.02.002
Citation: GONG Xiaobin, LIU Shiyi, XIA Tianyi, WEI Hua, CHEN Wansheng. Clinical application and research progress of apatinib in cancer treatment[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(2): 103-107,130. doi: 10.3969/j.issn.1006-0111.2018.02.002
参考文献 (45)

目录

    /

    返回文章
    返回